Today, a Director at AVEO Pharma (AVEO), Anthony Evnin, sold shares of AVEO for $2.14M.
See today’s analyst top recommended stocks >>
Currently, AVEO Pharma has an average volume of 1.8M.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $6.33, reflecting a 234.9% upside.
The insider sentiment on AVEO Pharma has been positive according to 70 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Anthony Evnin’s trades have generated a 44.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353.
